Logo-jnp
J Nephropathol. 2017;6(4): 368-373. doi: 10.15171/jnp.2017.61

Original Article

Role of corticosteroid therapy in IgA nephropathy; where do we stand?

Shankar Prasad Nagaraju * , Sindhura Lakshmi Koulmane Laxminarayana 2, Aswani Srinivas Mareddy 3, Srikanth Prasad 1, Sindhu Kaza 1, Srinivas Shenoy 1, Karan Saraf 1, Dharshan Rangaswamy 1, Ravindra Prabhu Attur 1, Rajeevalochana Parthasarathy 4, Uday Venkat Mateti 5, Vasudeva Guddattu 6, Mahesha Vankalakunti 7

Cited by CrossRef: 1

1- Han S, Yao T, Lu Y, Chen M, Xu Y, Wang Y. Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis. Front Pharmacol. 2021;11 [Crossref]
2- Shadab S, Bansal S, Wijewickrama E, Alam M, Shah D, Bagchi S. Challenges in access to novel IgA nephropathy therapeutics in South Asia. The Lancet Regional Health - Southeast Asia. 2026;:100812 [Crossref]